| [1] |
Bade BC, Dela Cruz CS. Lung Cancer 2020: Epidemiology, Etiology, and Prevention. Clin Chest Med, 2020, 41(1): 1-24. doi:10.1016/j.ccm.2019.10.001.
pmid: 32008623
|
| [2] |
周琪, 段亮, 姜格宁, 等. 青年男性肺腺癌临床特征对预后的影响. 中国癌症杂志, 2009, 19(8): 631-633. doi:10.3969/j.issn.1007-3639.2009.08.014.
|
| [3] |
Oliver AL. Lung Cancer: Epidemiology and Screening. Surg Clin North Am, 2022, 102(3): 335-344. doi:10.1016/j.suc.2021.12.001.
pmid: 35671760
|
| [4] |
王忠照, 唐昊. 《中华医学会肺癌临床诊疗指南(2024版)》更新要点解读. 海军军医大学学报, 2025, 46(1): 17-23. doi:10.16781/j.CN31-2187/R.20240697.
|
| [5] |
姜紫薇, 郎筠岚, 姚云祥, 等. 线粒体在肿瘤能量代谢重编程中的研究进展. 中国实验诊断学, 2025, 29(6): 724-728. doi:10.3969/j.issn.1007-4287.2025.06.018.
|
| [6] |
Phan LM, Yeung SC, Lee MH. Cancer metabolic reprogramming: importance, main features, and potentials for precise targeted anti-cancer therapies. Cancer Biol Med, 2014, 11(1):1-19. doi:10.7497/j.issn.2095-3941.2014.01.001.
pmid: 24738035
|
| [7] |
Nong S, Han X, Xiang Y, et al. Metabolic reprogramming in cancer: Mechanisms and therapeutics. MedComm (2020), 2023, 4(2): e218. doi:10.1002/mco2.218.
|
| [8] |
Broadfield LA, Pane AA, Talebi A, et al. Lipid metabolism in cancer: New perspectives and emerging mechanisms. Dev Cell, 2021, 56(10): 1363-1393. doi:10.1016/j.devcel.2021.04.013.
pmid: 33945792
|
| [9] |
Martin-Perez M, Urdiroz-Urricelqui U, Bigas C, et al. The role of lipids in cancer progression and metastasis. Cell Metab, 2022, 34(11):1675-1699. doi:10.1016/j.cmet.2022.09.023.
pmid: 36261043
|
| [10] |
Zhao Y, Shen M, Wu L, et al. Stromal cells in the tumor microenvironment: accomplices of tumor progression? Cell Death Dis, 2023, 14(9): 587. doi:10.1038/s41419-023-06110-6.
pmid: 37666813
|
| [11] |
de Visser KE, Joyce JA. The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth. Cancer Cell, 2023, 41(3): 374-403. doi:10.1016/j.ccell.2023.02.016.
pmid: 36917948
|
| [12] |
Yang J, Li Y, Liu Q, et al. Brief introduction of medical database and data mining technology in big data era. J Evid Based Med, 2020, 13(1): 57-69. doi:10.1111/jebm.12373.
|
| [13] |
李鑫, 李梦玮, 张依楠, 等. 常用肿瘤基因分析方法及基于TCGA数据库的分析应用. 遗传, 2019, 41(3): 234-242. doi:10.16288/j.yczz.18-279.
|
| [14] |
Song R, Fond A, Li X, et al. The dual lipid desaturase/hydroxylase DEGS2 controls phytoceramide levels necessary to counter intestinal inflammation. Dis Model Mech, 2023, 16(9): dmm050043. doi:10.1242/dmm.050043.
|
| [15] |
Hua Y, Zhang G, Liu Y, et al. Regulation of sphingolipid metabolism in the immune microenvironment of gastric cancer: current insights and future directions. Front Oncol, 2025, 15: 1604227. doi:10.3389/fonc.2025.1604227.
|
| [16] |
Janneh AH, Ogretmen B. Targeting Sphingolipid Metabolism as a Therapeutic Strategy in Cancer Treatment. Cancers (Basel), 2022, 14(9): 2183. doi:10.3390/cancers14092183.
|
| [17] |
Ota A, Morita H, Naganuma T, et al. Bifunctional DEGS2 has higher hydroxylase activity toward substrates with very-long-chain fatty acids in the production of phytosphingosine ceramides. J Biol Chem, 2023, 299(4):104603. doi:10.1016/j.jbc.2023.104603.
|
| [18] |
Luo Y, Yu J, Li Q, et al. Delta 4-desaturase sphingolipid 2 enhances prostate cancer stem-like traits through phytoceramide-mediated PI3K-AKT signaling pathway. Carcinogenesis, 2025, 46(2): bgaf024. doi:10.1093/carcin/bgaf024.
|
| [19] |
Guo W, Zhang C, Feng P, et al. M6A methylation of DEGS2, a key ceramide-synthesizing enzyme, is involved in colorectal cancer progression through ceramide synthesis. Oncogene, 2021, 40(40):5913-5924. doi:10.1038/s41388-021-01987-z.
|